Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDViridian Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 8 | -$1.56 | -$0.62 | -$1.09 |
| Q2 2024 | 8 | -$1.25 | -$0.49 | -$0.87 |
| Q3 2024 | 8 | -$1.52 | -$0.60 | -$1.06 |
| Q4 2024 | 10 | -$1.16 | -$0.87 | -$1.04 |
| Q1 2025 | 4 | -$1.07 | -$1.00 | -$1.04 |
| Q2 2025 | 2 | -$1.54 | -$0.61 | -$1.08 |
| Q3 2025 | 2 | -$1.55 | -$0.61 | -$1.08 |
| Q4 2025 | 2 | -$1.70 | -$0.67 | -$1.18 |
| Q1 2026 | 1 | -$1.94 | -$0.77 | -$1.35 |
| Q2 2026 | 1 | -$1.86 | -$0.73 | -$1.30 |
| Q3 2026 | 1 | -$1.68 | -$0.66 | -$1.17 |
| Q4 2026 | 1 | -$2.42 | -$0.95 | -$1.69 |
Viridian Therapeutics, Inc. Earnings Date And Information
Viridian Therapeutics, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-1.15 earnings per share for the quarter, missing analysts' consensus estimates of $-1.11 by $0.04. The company had revenue of 86,000 for the quarter and had revenue of 314,000 for the year. Viridian Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-5.31 diluted earnings per share) and currently has a price-to-earnings ratio of -4.99. Viridian Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Viridian Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$1.11 | -$1.15 | -0.04 | $84,917 | $86,000 |
| 08/08/2024 | Q2 2024 | -$0.87 | -$1.02 | -0.15 | $78,154 | $72,000 |
| 05/08/2024 | Q1 2024 | -$0.79 | $72,000 | |||
| 02/27/2024 | Q4 2023 | -$1.08 | -$1.35 | -0.27 | $72,000 | |
| 11/13/2023 | Q3 2023 | -$1.22 | -$1.09 | 0.13 | $145,250 | $72,000 |
| 08/08/2023 | Q2 2023 | -$1.26 | -$1.27 | -0.01 | $254,000 | $72,000 |
| 05/10/2023 | Q1 2023 | -$1.61 | $98,000 | |||
| 03/09/2023 | Q4 2022 | -$1.05 | $105,000 | |||
| 11/14/2022 | Q3 2022 | -$0.87 | -$0.83 | 0.04 | $303,333 | $1.20 M |
| 08/15/2022 | Q2 2022 | -$0.86 | -$1.06 | -0.2 | $270,333 | $256,000 |
| 05/13/2022 | Q1 2022 | -$0.98 | $216,000 | |||
| 03/11/2022 | Q4 2021 | -$2.59 | $214,000 | |||
| 11/05/2021 | Q3 2021 | -$1.26 | $454,200 | $208,000 | ||
| 08/12/2021 | Q2 2021 | -$2.22 | $1.09 M | |||
| 05/07/2021 | Q1 2021 | -$2.91 | $1.45 M | |||
| 03/26/2021 | Q4 2020 | -$23.07 | $54,000 | |||
| 11/12/2020 | Q3 2020 | -$1.48 | $206,000 | $0 | ||
| 08/05/2020 | Q2 2020 | -$2.47 | -$1.82 | 0.65 | $645,250 | $168,000 |
| 05/08/2020 | Q1 2020 | -$2.65 | $828,000 | |||
| 03/12/2020 | Q4 2019 | -$4.69 | $880,000 |
Viridian Therapeutics, Inc. Earnings: FAQ's
When is Viridian Therapeutics, Inc.'s earnings date?
Viridian Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
How can I listen to Viridian Therapeutics, Inc.'s earnings conference
call?
The conference call for Viridian Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Viridian Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Viridian Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Viridian Therapeutics, Inc. generate each year?
Viridian Therapeutics, Inc. (:VRDN) has a recorded annual revenue of $314,000.
How much profit does Viridian Therapeutics, Inc. generate each year?
Viridian Therapeutics, Inc. (:VRDN) has a recorded net income of $314,000. Viridian Therapeutics, Inc. has generated $-5.31 earnings per share over the last four quarters.
What is Viridian Therapeutics, Inc.'s price-to-earnings ratio?
Viridian Therapeutics, Inc. (:VRDN) has a price-to-earnings ratio of -4.99 and price/earnings-to-growth ratio is 3.53.